

## Enfortumab vedotin-ejfv

Cat. No.:	HY-P99016A
CAS No.:	1346452-25-2
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### Enfortumab vedotin-ejfv

#### BIOLOGICAL ACTIVITY

Description	Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma <sup>[1]</sup> .
In Vitro	Enfortumab vedotin-ejfv is a fully human IgG1-kappa antibody conjugated to the microtubule-disrupting agent, monomethyl auristatin E (MMAE), via a protease-cleavable maleimidocaproyl valine-citrulline linker (SGD-1006) <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### REFERENCES

[1]. Halford Z, et al. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma. *Ann Pharmacother*. 2021 Jun;55(6):772-782.

[2]. Chang E, et al. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma. *Clin Cancer Res*. 2021 Feb 15;27(4):922-927.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA